<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01156584</url>
  </required_header>
  <id_info>
    <org_study_id>Tg 511-08-01</org_study_id>
    <nct_id>NCT01156584</nct_id>
  </id_info>
  <brief_title>A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma</brief_title>
  <official_title>A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tocagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tocagen Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, ascending-dose trial of the safety and tolerability of&#xD;
      increasing doses of Toca 511, a Retroviral Replicating Vector (RRV), administered to patients&#xD;
      with recurrent high grade glioma (rHGG) who have undergone surgery followed by adjuvant&#xD;
      radiation therapy and chemotherapy. Patients will receive Toca 511 either via stereotactic,&#xD;
      transcranial injection into their tumor or as an intravenous injection given daily for 3 &amp; 5&#xD;
      days, depending on cohort. Approximately 3-4 weeks following injection of the RRV, treatment&#xD;
      with Toca FC, an antifungal agent, will commence and will be repeated approximately every 6&#xD;
      weeks until study completion. After completion of this study, all patients will be eligible&#xD;
      for enrollment and encouraged to enter a long-term continuation protocol that enables&#xD;
      additional Toca FC treatment cycles to be given, as well as permits the collection of&#xD;
      long-term safety and survival data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">August 18, 2016</completion_date>
  <primary_completion_date type="Actual">August 18, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Feasible, Safe and Well Tolerated Dose of Toca 511</measure>
    <time_frame>8-10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of repeated treatment with Toca FC following administration of Toca 511</measure>
    <time_frame>6 months</time_frame>
    <description>Review of adverse events including laboratory safety data (specifically any Grade 3 or higher non-hematologic toxicity or any Grade 4 or higher hematologic toxicity, felt to be related to Toca 511 or the Toca 511/Toca FC combination)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of Subjects</measure>
    <time_frame>Overall survivial, Overall survivial at 6 months (OS6), 9 months (OS9), and 12 months (OS12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate progression free survival (PFS) at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Anaplastic Oligodendroglioma</condition>
  <condition>Anaplastic Oligoastrocytoma</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toca 511 vector/ Toca FC prodrug</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Toca 511 vector</intervention_name>
    <description>Single, stereotactic, transcranial, intratumoral injection or intravenous injection</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>Retroviral Replicating Vector (RRV)</other_name>
    <other_name>Gene Therapy</other_name>
    <other_name>Gene Transfer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toca FC</intervention_name>
    <description>4-6 week cycles of Toca FC. Doses evaluated from 120 mg/kg/day or 300 mg/kg/day. Duration of dosing evaluated: 6 days, 7 days or 14 days.</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>flucytosine, 5-FC, 5-FC XR, Toca FC (extended release flucytosine)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  at least 18 years of age&#xD;
&#xD;
          -  for intratumoral cohorts, supratentorial HGG (WHO grade III or IV)&#xD;
&#xD;
          -  technically unresectable HGG&#xD;
&#xD;
          -  initial definitive therapy such as surgery with or without adjuvant radiation&#xD;
&#xD;
          -  subject elected not to undergo treatment with Gliadel wafer&#xD;
&#xD;
          -  if receiving corticosteroids, dose is stable or decreasing for past 7 days&#xD;
&#xD;
          -  KPS: at least 70&#xD;
&#xD;
          -  absolute neutrophil count &gt; 1500/mm^3&#xD;
&#xD;
          -  absolute lymphocyte count &gt; 500/mm^3&#xD;
&#xD;
          -  platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  hemoglobin &gt; 10 g/dL&#xD;
&#xD;
          -  for intratumoral cohort, coagulation profile favorable to surgery&#xD;
&#xD;
          -  estimated glomerular filtration rate &gt; 50 mL/min&#xD;
&#xD;
          -  ALT &lt; 3 times ULN and bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
          -  negative serum pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cytotoxic therapy within the past 4 weeks (6 weeks for BCNU/CCNU)&#xD;
&#xD;
          -  more than 2 recurrences including present recurrence&#xD;
&#xD;
          -  Gliadel wafer or wafers implanted within the past 8 weeks&#xD;
&#xD;
          -  taking more than 8 mg of dexamethasone per day&#xD;
&#xD;
          -  for intratumoral cohorts, injection of tumor would require violation of ventricular&#xD;
             system&#xD;
&#xD;
          -  any infection requiring antibiotic, anticoagulant, or antiplatelet agents within the&#xD;
             past 4 weeks&#xD;
&#xD;
          -  for intratumoral cohort, bleeding diathesis or use of anticoagulants/antiplatelet&#xD;
             agents that cannot be stopped&#xD;
&#xD;
          -  allergy or intolerance to 5-FC&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  g.i. condition that would prevent ingestion or absorption of 5-FC&#xD;
&#xD;
          -  any investigational treatment within the past 30 days&#xD;
&#xD;
          -  pregnant or breast feeding&#xD;
&#xD;
          -  received Avastin&#xD;
&#xD;
          -  history of prior malignancy, excluding basal or squamous cell carcinoma of the skin,&#xD;
             with an expected survival of less than 5 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asha Das, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tocagen Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manish Aghi, MD, NS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.braintumor.org</url>
    <description>Website for the National Brain Tumor Society</description>
  </link>
  <reference>
    <citation>Tai CK, Wang WJ, Chen TC, Kasahara N. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther. 2005 Nov;12(5):842-51.</citation>
    <PMID>16257382</PMID>
  </reference>
  <reference>
    <citation>Ostertag D, Amundson KK, Lopez Espinoza F, Martin B, Buckley T, Galvão da Silva AP, Lin AH, Valenta DT, Perez OD, Ibañez CE, Chen CI, Pettersson PL, Burnett R, Daublebsky V, Hlavaty J, Gunzburg W, Kasahara N, Gruber HE, Jolly DJ, Robbins JM. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol. 2012 Feb;14(2):145-59. doi: 10.1093/neuonc/nor199. Epub 2011 Nov 9.</citation>
    <PMID>22070930</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>July 1, 2010</study_first_submitted>
  <study_first_submitted_qc>July 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 5, 2010</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glioma</keyword>
  <keyword>glioblastoma</keyword>
  <keyword>glioblastoma multiforme</keyword>
  <keyword>Grade IV astrocytoma</keyword>
  <keyword>brain cancer</keyword>
  <keyword>recurrent glioblastoma</keyword>
  <keyword>GBM</keyword>
  <keyword>AA</keyword>
  <keyword>AOD</keyword>
  <keyword>anaplastic astrocytoma</keyword>
  <keyword>anaplastic oligodendroglioma</keyword>
  <keyword>anaplastic oligoastrocytoma</keyword>
  <keyword>malignant glioma</keyword>
  <keyword>high grade glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flucytosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

